{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:57:02Z","timestamp":1781877422004,"version":"3.54.5"},"reference-count":113,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0271","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T18:06:06Z","timestamp":1745345166000},"page":"847-862","source":"Crossref","is-referenced-by-count":4,"title":["Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2631","authenticated-orcid":false,"given":"Yasuo","family":"Imanishi","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Furukubo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shirasagi Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeichi","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shirasagi Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy  (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785\u2013795.","DOI":"10.1001\/jama.285.6.785"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Al-Sari UA, Tobias J, Clark E (2016) Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. Osteoporos Int 27: 2891\u20132900.","DOI":"10.1007\/s00198-016-3648-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11: 556\u2013561.","DOI":"10.1007\/s001980070075"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, et al. (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301: 513\u2013521.","DOI":"10.1001\/jama.2009.50"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, et al. (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31: 247\u2013257.","DOI":"10.1007\/s00774-013-0447-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, et al. (2021) European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant 36: 42\u201359.","DOI":"10.1093\/ndt\/gfaa192"},{"key":"7","unstructured":"7 Japanese Society of Nephrology (ed) (2023) Evidence-based Clinical Practice Guideline for CKD 2023. Tokyo Igakusha, Tokyo, Japan (In Japanese)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Evenepoel P, Behets GJS, Laurent MR, D\u2019Haese PC (2017) Update on the role of bone biopsy in the management of patients with CKD-MBD. J Nephrol 30: 645\u2013652.","DOI":"10.1007\/s40620-017-0424-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Takeuchi M, Shinkawa K, Yanagita M, Kawakami K (2021) Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data. Clin Kidney J 14: 2197\u20132202.","DOI":"10.1093\/ckj\/sfab016"},{"key":"10","unstructured":"10 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 76: S1\u2013S130."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 7: 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, et al. (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7: 810\u2013819.","DOI":"10.2215\/CJN.08680811"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, et al. (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945\u20131953.","DOI":"10.1038\/sj.ki.5000414"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ferreira AC, Cohen-Solal M, D\u2019Haese PC, Ferreira A (2021) The role of bone biopsy in the management of CKD-MBD. Calcif Tissue Int 108: 528\u2013538.","DOI":"10.1007\/s00223-021-00838-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Bover J, Ure\u00f1a-Torres P, Torregrosa JV, Rodr\u00edguez-Garc\u00eda M, Castro-Alonso C, et al. (2018) Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. Nefrologia (Engl Ed) 38: 476\u2013490.","DOI":"10.1016\/j.nefroe.2018.10.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Fusaro M, Re Sart\u00f2 GV, Gallieni M, Cosmai L, Messa P, et al. (2022) Time for revival of bone biopsy with histomorphometric analysis in Chronic Kidney Disease (CKD): moving from skepticism to pragmatism. Nutrients 14: 1742.","DOI":"10.3390\/nu14091742"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Saito M, Fujii K, Mori Y, Marumo K (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN\/Kob rats. Osteoporos Int 17: 1514\u20131523.","DOI":"10.1007\/s00198-006-0155-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17: 986\u2013995.","DOI":"10.1007\/s00198-006-0087-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Mitome J, Yamamoto H, Saito M, Yokoyama K, Marumo K, et al. (2011) Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 88: 521\u2013529.","DOI":"10.1007\/s00223-011-9488-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, et al. (2014) Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res 29: 399\u2013407.","DOI":"10.1002\/jbmr.2048"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, et al. (2013) Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28: 1811\u20131820.","DOI":"10.1002\/jbmr.1916"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, et al. (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396\u2013399.","DOI":"10.1046\/j.1523-1755.2000.00178.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115\u20131121.","DOI":"10.1053\/ajkd.2000.19812"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, et al. (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70: 1358\u20131366.","DOI":"10.1038\/sj.ki.5001754"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, et al. (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47: 149\u2013156.","DOI":"10.1053\/j.ajkd.2005.09.024"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Dukas L, Schacht E, St\u00e4helin HB (2005) In elderly men and women treated for osteoporosis a low creatinine clearance of &lt;65 mL\/min is a risk factor for falls and fractures. Osteoporos Int 16: 1683\u20131690.","DOI":"10.1007\/s00198-005-1903-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Lin ZZ, Wang JJ, Chung CR, Huang PC, Su BA, et al. (2014) Epidemiology and mortality of hip fracture among patients on dialysis: Taiwan National Cohort Study. Bone 64: 235\u2013239.","DOI":"10.1016\/j.bone.2014.04.017"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, et al. (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85: 166\u2013173.","DOI":"10.1038\/ki.2013.279"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, et al. (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86: 810\u2013818.","DOI":"10.1038\/ki.2013.547"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Naylor KL, Leslie WD, Hodsman AB, Rush DN, Garg AX (2014) FRAX predicts fracture risk in kidney transplant recipients. Transplantation 97: 940\u2013945.","DOI":"10.1097\/01.TP.0000438200.84154.1a"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, et al. (2015) Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS One 10: e0122691.","DOI":"10.1371\/journal.pone.0122691"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Hung LW, Hwang YT, Huang GS, Liang CC, Lin J (2017) The influence of renal dialysis and hip fracture sites on the 10-year mortality of elderly hip fracture patients: A nationwide population-based observational study. Medicine (Baltimore) 96: e7618.","DOI":"10.1097\/MD.0000000000007618"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Desbiens LC, Goupil R, Madore F, Mac-Way F (2020) Incidence of fractures in middle-aged individuals with early chronic kidney disease: a population-based analysis of CARTaGENE. Nephrol Dial Transplant 35: 1712\u20131721.","DOI":"10.1093\/ndt\/gfz259"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B (2021) A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine 73: 509\u2013529.","DOI":"10.1007\/s12020-021-02735-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, et al. (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18: 282\u2013286.","DOI":"10.1681\/ASN.2006050546"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, et al. (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167: 133\u2013139.","DOI":"10.1001\/archinte.167.2.133"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Hall RK, Sloane R, Pieper C, Van Houtven C, LaFleur J, et al. (2018) Competing risks of fracture and death in older adults with chronic kidney disease. J Am Geriatr Soc 66: 532\u2013538.","DOI":"10.1111\/jgs.15256"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Vilaca T, Salam S, Schini M, Harnan S, Sutton A, et al. (2020) Risks of hip and nonvertebral fractures in patients with CKD G3a-G5D: A systematic review and meta-analysis. Am J Kidney Dis 76: 521\u2013532.","DOI":"10.1053\/j.ajkd.2020.02.450"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, et al. (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31: 315\u2013321.","DOI":"10.1007\/s00774-012-0411-z"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Imanishi Y, Taniuchi S, Kodama S, Yoshida H, Ito T, et al. (2025) Real-world fracture risk, osteoporosis treatment status, and mortality of Japanese non-dialysis patients with chronic kidney disease stages G3-5. Clin Exp Nephrol 29: 236\u2013247.","DOI":"10.1007\/s10157-024-02562-y"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Przedlacki J, Buczy\u0144ska-Chyl J, Ko\u017ami\u0144ski P, Niemczyk E, Wojtaszek E, et al. (2018) The utility of FRAX<sup>\u00ae<\/sup> in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study. Osteoporos Int 29: 1105\u20131115.","DOI":"10.1007\/s00198-018-4406-z"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Tran J, Ayers E, Verghese J, Abramowitz MK (2019) Gait abnormalities and the risk of falls in CKD. Clin J Am Soc Nephrol 14: 983\u2013993.","DOI":"10.2215\/CJN.13871118"},{"key":"43","unstructured":"43 Foundation NK (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1\u2013S266."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, et al. (2021) Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int 32: 2397\u20132405.","DOI":"10.1007\/s00198-021-05975-7"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45 Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, et al. (1994) Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58: 912\u2013915.","DOI":"10.1097\/00007890-199410000-00009"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 O\u2019Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL (2002) Risk factors for fractures in kidney transplantation. Transplantation 74: 362\u2013366.","DOI":"10.1097\/00007890-200208150-00012"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47 Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N (2009) Risk of fractures after renal transplantation in the United States. Transplantation 87: 1846\u20131851.","DOI":"10.1097\/TP.0b013e3181a6bbda"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Bellorin-Font E, Rojas E, Martin KJ (2022) Bone disease in chronic kidney disease and kidney transplant. Nutrients 15: 167.","DOI":"10.3390\/nu15010167"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Khairallah P, Nickolas TL (2022) Bone and mineral disease in kidney transplant recipients. Clin J Am Soc Nephrol 17: 121\u2013130.","DOI":"10.2215\/CJN.03410321"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Patel S, Kwan JT, McCloskey E, McGee G, Thomas G, et al. (2001) Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 16: 1863\u20131870.","DOI":"10.1359\/jbmr.2001.16.10.1863"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Lobo PI, Cortez MS, Stevenson W, Pruett TL (1995) Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 9: 277\u2013281.","DOI":"10.1111\/j.1399-0012.1995.tb00336.x"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Cianciolo G, Cozzolino M (2016) FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde. Clin Kidney J 9: 665\u2013668.","DOI":"10.1093\/ckj\/sfw072"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, et al. (2019) Bone mineral density, bone turnover markers, and incident fractures in <i>de novo<\/i> kidney transplant recipients. Kidney Int 95: 1461\u20131470.","DOI":"10.1016\/j.kint.2018.12.024"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Kanazawa I, Inaba M, Inoue D, Uenishi K, Saito M, et al. (2020) Executive summary of clinical practice guide on fracture risk in lifestyle diseases. J Bone Miner Metab 38: 746\u2013758.","DOI":"10.1007\/s00774-020-01149-3"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Japanese Society of  Nephrology (2024) Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin Exp Nephrol 28: 473\u2013495.","DOI":"10.1007\/s10157-024-02497-4"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Hara T, Hijikata Y, Matsubara Y, Watanabe N (2021) Pharmacological interventions <i>versus<\/i> placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database Syst Rev 7: Cd013424.","DOI":"10.1002\/14651858.CD013424.pub2"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Hashimoto H, Shikuma S, Mandai S, Adachi S, Uchida S (2021) Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients. Sci Rep 11: 1648.","DOI":"10.1038\/s41598-021-81287-4"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Phannajit J, Wonghakaeo N, Takkavatakarn K, Asawavichienjinda T, Praditpornsilpa K, et al. (2022) The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials. J Nephrol 35: 473\u2013491.","DOI":"10.1007\/s40620-021-01065-3"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, et al. (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407\u20131415.","DOI":"10.1681\/ASN.2012030223"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Di Iorio B, Bellasi A, Russo D (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 7: 487\u2013493.","DOI":"10.2215\/CJN.03820411"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, et al. (2018) Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 8: Cd006023.","DOI":"10.1002\/14651858.CD006023.pub3"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, et al. (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358\u2013363.","DOI":"10.1136\/bmj.310.6976.358"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86: 3618\u20133628.","DOI":"10.1210\/jcem.86.8.7703"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Rathod A, Bonny O, Guessous I, Suter PM, Conen D, et al. (2015) Association of urinary calcium excretion with serum calcium and vitamin D levels. Clin J Am Soc Nephrol 10: 452\u2013462.","DOI":"10.2215\/CJN.12511213"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators\u2014mechanisms of action and application to clinical practice. N Engl J Med 348: 618\u2013629.","DOI":"10.1056\/NEJMra022219"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, et al. (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14: 793\u2013800.","DOI":"10.1007\/s00198-003-1424-1"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Itabashi A, Yoh K, Chines AA, Miki T, Takada M, et al. (2011) Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 26: 519\u2013529.","DOI":"10.1002\/jbmr.252"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, et al. (2011) Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int 79: 241\u2013249.","DOI":"10.1038\/ki.2010.378"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Masaki H, Imanishi Y, Naka H, Nagata Y, Kurajoh M, et al. (2020) Bazedoxifene improves renal function and increases renal phosphate excretion in patients with postmenopausal osteoporosis. J Bone Miner Metab 38: 405\u2013411.","DOI":"10.1007\/s00774-019-01073-1"},{"key":"70","doi-asserted-by":"publisher","unstructured":"70 Adami S, Palacios S, Rizzoli R, Levine AB, Sutradhar S, et al. (2014) The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric 17: 273\u2013284.","DOI":"10.3109\/13697137.2013.830605"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE (2008) The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19: 1430\u20131438.","DOI":"10.1681\/ASN.2007050555"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Weisinger JR, Heilberg IP, Hern\u00e1ndez E, Carlini R, Bellorin-Font E (2003) Selective estrogen receptor modulators in chronic renal failure. Kidney Int Suppl 85: S62\u2013S65.","DOI":"10.1046\/j.1523-1755.63.s85.15.x"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Coxon FP, Helfrich MH, Van\u2019t Hof R, Sebti S, Ralston SH, et al. (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15: 1467\u20131476.","DOI":"10.1359\/jbmr.2000.15.8.1467"},{"key":"74","doi-asserted-by":"publisher","unstructured":"74 Masarachia P, Weinreb M, Balena R, Rodan GA (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281\u2013290.","DOI":"10.1016\/8756-3282(96)00182-2"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Sato M, Grasser W, Endo N, Akins R, Simmons H, et al. (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095\u20132105.","DOI":"10.1172\/JCI115539"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, et al. (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94: 3215\u20133225.","DOI":"10.1210\/jc.2008-2765"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, et al. (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22: 503\u2013508.","DOI":"10.1359\/jbmr.070112"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, et al. (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105\u20132115.","DOI":"10.1359\/JBMR.050817"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, et al. (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10: 183\u2013192.","DOI":"10.1007\/s001980050214"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, et al. (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22: 469\u2013478.","DOI":"10.1007\/s00774-004-0509-z"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27: 1471\u20131479.","DOI":"10.1002\/jbmr.1613"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, et al. (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 1829\u20131835.","DOI":"10.1002\/jbmr.403"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Iseri K, Watanabe M, Yoshikawa H, Mitsui H, Endo T, et al. (2019) Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: A randomized, controlled trial. J Bone Miner Res 34: 1014\u20131024.","DOI":"10.1002\/jbmr.3676"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Thongprayoon C, Acharya P, Aeddula NR, Torres-Ortiz A, Bathini T, et al. (2019) Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. Arch Osteoporos 14: 35.","DOI":"10.1007\/s11657-019-0587-0"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Miyaoka D, Imanishi Y, Kato E, Toi N, Nagata Y, et al. (2020) Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine 69: 642\u2013649.","DOI":"10.1007\/s12020-020-02401-6"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, et al. (2019) Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int 30: 241\u2013249.","DOI":"10.1007\/s00198-018-4688-1"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Chen J, Smerdely P (2017) Hypocalcaemia after denosumab in older people following fracture. Osteoporos Int 28: 517\u2013522.","DOI":"10.1007\/s00198-016-3755-8"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, et al. (2015) Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab 100: 2784\u20132792.","DOI":"10.1210\/jc.2015-1259"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, et al. (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int 29: 1737\u20131745.","DOI":"10.1007\/s00198-018-4533-6"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Huynh AL, Baker ST, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf 25: 1274\u20131278.","DOI":"10.1002\/pds.4045"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, et al. (2018) Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33: 190\u2013198.","DOI":"10.1002\/jbmr.3337"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, et al. (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases. J Bone Miner Res 32: 1291\u20131296.","DOI":"10.1002\/jbmr.3110"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102: 354\u2013358.","DOI":"10.1210\/jc.2016-3170"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, et al. (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96: 972\u2013980.","DOI":"10.1210\/jc.2010-1502"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Isogai Y, Akatsu T, Ishizuya T, Yamaguchi A, Hori M, et al. (1996) Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res 11: 1384\u20131393.","DOI":"10.1002\/jbmr.5650111003"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G (2017) One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res 32: 24\u201333.","DOI":"10.1002\/jbmr.3003"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18: 59\u201368.","DOI":"10.1007\/s00198-006-0189-8"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, et al. (2022) Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: The phase 3 ACTIVE-J study. J Clin Endocrinol Metab 107: e4222\u2013e4231.","DOI":"10.1210\/clinem\/dgac486"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Gordon PL, Frassetto LA (2010) Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis 55: 941\u2013956.","DOI":"10.1053\/j.ajkd.2010.02.338"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Cejka D, Haas M (2011) Should teriparatide ever be used for adynamic bone disease? Semin Dial 24: 431\u2013433.","DOI":"10.1111\/j.1525-139X.2011.00911.x"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H (2016) Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging 11: 1653\u20131659.","DOI":"10.2147\/CIA.S120175"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, et al. (2016) Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int 27: 1441\u20131450.","DOI":"10.1007\/s00198-015-3377-6"},{"key":"103","doi-asserted-by":"publisher","unstructured":"103 Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, et al. (2016) Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 84: 148\u2013159.","DOI":"10.1016\/j.bone.2015.12.013"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, et al. (2003) Osteocyte control of bone formation <i>via<\/i> sclerostin, a novel BMP antagonist. EMBO J 22: 6267\u20136276.","DOI":"10.1093\/emboj\/cdg599"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, et al. (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375: 1532\u20131543.","DOI":"10.1056\/NEJMoa1607948"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J (2022) Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab 40: 677\u2013687.","DOI":"10.1007\/s00774-022-01332-8"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, et al. (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37: 1437\u20131445.","DOI":"10.1002\/jbmr.4563"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Hsu CP, Maddox J, Block G, Bartley Y, Yu Z (2022) Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J Clin Pharmacol 62: 1132\u20131141.","DOI":"10.1002\/jcph.2050"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, et al. (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39: 1082\u20131090.","DOI":"10.1007\/s00774-021-01253-y"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110 Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, et al. (2023) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: An observational study. Calcif Tissue Int 112: 34\u201344.","DOI":"10.1007\/s00223-022-01031-6"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 4: 727\u2013740.","DOI":"10.1517\/17460440903022743"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112 Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Cinacalcet in hyperfunctioning parathyroid diseases. Ther Apher Dial 13 Suppl 1: S7\u2013S11.","DOI":"10.1111\/j.1744-9987.2009.00768.x"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 Rodr\u00edguez N, G\u00f3mez M, Rico N, Mar\u00eda Campistol J, Maduell F (2019) Vancomycin hemodialysis: Clearance differences between high-flux hemodialysis and on-line hemodiafiltration. Artif Organs 43: 261\u2013269.","DOI":"10.1111\/aor.13368"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/8\/72_EJ24-0271\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T03:34:22Z","timestamp":1754105662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/8\/72_EJ24-0271\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0271","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0271"}}